Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

Vaccine
Cara UsherMichael Barry

Abstract

We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was euro17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (euro3400 to euro38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.

References

May 1, 1998·Human Pathology·J J O'LearyC T Doyle
Sep 8, 2000·PharmacoEconomics·A H Briggs
Jan 21, 2003·Emerging Infectious Diseases·Gillian D Sanders, Al V Taira
Feb 13, 2004·International Journal of Cancer. Journal International Du Cancer·Binh H YangZuo-Feng Zhang
May 17, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Gary M CliffordJeanne M Pimenta
Jun 13, 2006·Contemporary Clinical Trials·Seonaidh C CottonUNKNOWN TOMBOLA group
Apr 4, 2007·International Journal of Cancer. Journal International Du Cancer·Jennifer S SmithGary M Clifford
May 15, 2007·The New England Journal of Medicine·UNKNOWN FUTURE II Study Group
Jul 4, 2007·Vaccine·Sue J GoldieEduardo L Franco
Aug 21, 2007·Vaccine·Gary Michael GinsbergJacob Bornstein
Aug 29, 2007·International Journal of Cancer. Journal International Du Cancer·Kristjan SigurdssonThorunn Rafnar
Dec 28, 2007·European Journal of Public Health·Lesley TilsonMichael Barry
Jan 26, 2008·International Journal of Technology Assessment in Health Care·Christine BergeronVanessa Remy
Feb 19, 2008·Cost Effectiveness and Resource Allocation : C/E·Shalini L KulasingamEvan R Myers
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Lesley TilsonMichael Barry

❮ Previous
Next ❯

Citations

Feb 12, 2011·Internal and Emergency Medicine·Daniela KolevaLivio Garattini
Apr 16, 2010·International Journal of Technology Assessment in Health Care·Jens Olsen, Martin Rudbeck Jepsen
Aug 20, 2010·Sexual Health·Philippe Beutels, Mark Jit
Mar 13, 2010·PharmacoEconomics·Lesley TilsonMichael Barry
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Josephine MauskopfBaudouin Standaert
Jun 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Lesley Tilson, Michael Barry
Oct 7, 2010·Expert Review of Vaccines·Maria A de PeuterSibilia Quilici
Sep 1, 2009·Gaceta sanitaria·Roberto Pradas VelascoJavier Mar
Sep 2, 2015·Nature Reviews. Clinical Oncology·F Xavier BoschJack Cuzick
Jun 18, 2011·Journal of Evaluation in Clinical Practice·Meng-Kan ChenHsiu-Hsi Chen
Jul 15, 2016·Archives of public health = Archives belges de santé publique·Cara UsherCathal Walsh
May 5, 2017·MMWR. Surveillance Summaries : Morbidity and Mortality Weekly Report. Surveillance Summaries·Walter W WilliamsAmy Parker Fiebelkorn
Dec 7, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Dimitris KostarasKostas Athanasakis
Dec 12, 2018·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Mireia DiazLaia Bruni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bowen's Disease

Bowen's disease is thought of as an easily-treatable early stage of skin cancer, characterized by red, scaly patches on the skin. Discover the latest research on Bowen's disease here.